79
Views
1
CrossRef citations to date
0
Altmetric
Review

Antibiotic and non-antibiotic tetracycline patents: 2002 – 2007

, &
Pages 69-82 | Published online: 18 Jan 2008

Bibliography

  • Sum P-E. Tetracyclines. Kirk-Othmer Encyclopedia of Chemical Technology. 5th Edition, 2007;(24):592-612
  • Nelson ML, Ismail MY. The antibiotic and non-antibiotic tetracyclines. Compr Med Chem II 2006;(7):597-628
  • Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin Drug Actions Reactions Interactions 2007;25(2):133-5
  • Lode H, Heinzl S. Tigecycline – new glycylcycline antibiotic. Arzneimitteltherapie 2006;24(10):338-41; Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006;28(8):1079-106
  • Nelson ML, Ismail M, Bowser T, et al. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States; 2006
  • Charest MG, Lerner CD, Brubaker JD, et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005;308(5720):395-8
  • Charest MG, Siegel DR, Myers AG. Synthesis of (-)-tetracycline. J Am Chem Soc 2005;127(23):8292-3
  • The President and Fellows of Harvard College. WO2007117639 (2007)
  • Duggar BM, Aureomycin. Ann NY Acad Sci 1948;51:177-81
  • American Cyanimid Co., USA. US2482055 (1949)
  • Chas. Pfizer, USA. US2516080 (1950)
  • Blackwood RK, Beereboom JJ, Rennhard HH, et al. 6-Methylenetetracyclines. I. A new class of tetracycline antibiotics. J Am Chem Soc 1961;83:2773-5
  • Stephens CR, Beereboom JJ, Rennhard HH, et al. 6-Deoxytetracyclines. IV. Preparation, C-6 stereochemistry, and reactions. J Am Chem Soc 1963;85(17):2643-52
  • Church R, Schaub R, Weiss M. Synthesis of 7-dimethylamino-6-demethyl-6-deoxytetracycline (minocycline) via 9-nitro-6-demethyl-6-deoxytetracycline. J Org Chem 1971;36(5):723-5
  • Garvin J. Research is in my blood': Dr Lorne Golub, developer of periostat, receives the ADA's gold medal award for excellence in dental research. J Am Dent Assoc 2006;137(9):1281-2
  • Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodont Res 1983;18(5):516-26
  • Greenwald RA, Golub LM, Lavietes B, et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheum 1987;14(1):28-32
  • Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007;13(4):517-26
  • Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006;24(9):1389-94
  • Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke. Neurology 2007;69:1404-10
  • Jordan J, Fernandez-Gomez FJ, Ramos M, et al. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007;4(3):225-31
  • Pasquale TR, Tan JS. Update on antimicrobial agents: new indications of older agents. Expert Opin Pharmacother 2005;6(10):1681-91
  • Parnham MJ. Antibiotics, inflammation, and its resolution: an overview. Antibiot Anti Inflamm Immunomod Agents 2005;25-47
  • Sum P-E, Lee VJ, Testa RT, et al. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994;37(1):184-8
  • Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001;1(5):464-9
  • Jones CH, Petersen P. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today 2005;41(10):637-59
  • American Cyanamid Co., USA. US5401863 (1995)
  • American Cyanamid Co., USA. US5281628 (1994)
  • American Cyanamid Co., USA. US5326759 (1994)
  • Pfizer, USA. US5834450 (1998)
  • Nelson ML, Ismail MY, McIntyre L, et al. Versatile and facile synthesis of diverse semi-synthetic tetracycline derivatives via Pd-catalyzed reactions. J Org Chem 2003;68(15):5838-51
  • Trustees of Tufts College; Paratek Pharmaceuticals, USA. US6500812 (2002)
  • Trustees of Tufts College; Paratek Pharmaceuticals, USA. US6849615 (2005)
  • Trustees of Tufts College, USA. US7067681 (2006)
  • Trustees of Tufts College, USA. US6617318 (2003)
  • Trustees of Tufts College, USA. US7094806 (2006)
  • Trustees of Tufts College, USA. US6624168 (2003)
  • Paratek Pharmaceuticals, USA. US6642270 (2003)
  • Paratek Pharmaceuticals, Trustees of Tufts College, USA. US6818635 (2004)
  • Paratek Pharmaceuticals, USA. US6683068 (2004)
  • Al-Awar RS, Ray JE, Schultz RM, et al. A convergent approach to cryptophicin 52 analogues:synthesis and biological evaluation of a novel series of fragment A epoxides and epichlohydrins. J Med Chem 2003;46(14):2985-3007
  • Paratek Pharmaceuticals, Trustees of Tufts College, USA. US6818634 (2004)
  • Paratek Pharmaceuticals, Trustees of Tufts College, USA. US6846939 (2005)
  • Bhatia B, Bowser T, Chen J, et al. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003
  • Nelson ML, Donatelli J, McKenney D, Levy SB. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States; 2006
  • Paratek Pharmaceuticals, USA. US2006287283 (2006)
  • Paratek Pharmaceuticals, USA. US7001918 (2006)
  • Paratek Pharmaceuticals, USA. US7208482 (2007)
  • Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updates 2004;7(3):195-208
  • Paratek Pharmaceuticals, USA. US7056902 (2006)
  • Paratek Pharmaceuticals, USA. WO2004006850 (2004)
  • Paratek Pharmaceuticals, USA. WO2006047671 (2006)
  • Paratek Pharmaceuticals, USA. WO2006084265 (2006)
  • Paratek Pharmaceuticals, USA. WO2007014154 (2007)
  • Paratek Pharmaceuticals, USA. WO2006047671 (2006)
  • Paratek Pharmaceuticals, USA. US6833365 (2002)
  • Paratek Pharmaceuticals, USA. WO2004038001 (2004)
  • Paratek Pharmaceuticals, USA. US6841546 (2004)
  • Paratek Pharmaceuticals, USA. US7045507 (2006)
  • Paratek Pharmaceuticals, USA. EO2003005971 (2003)
  • Paratek Pharmaceuticals, USA. WO2004038000 (2004)
  • Wyeth, USA. WO2006130500 (2006)
  • Wyeth, USA. WO2006130501 (2006)
  • Wyeth, USA. WO2006130418 (2006)
  • Wyeth, USA. WO2006130431 (2006)
  • Wyeth, USA. WO2007027599 (2007)
  • Wyeth, USA. WO2006088720 (2006)
  • Wyeth, USA. US7176225 (2007)
  • The President and Fellows of Harvard College, USA. WO2005112945 (2005)
  • Wang KK, Larner SF, Robinson G, Hayes RL. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol 2006;19:514-9
  • Kampfl A, Posmantur RM, Zhao X, et al. Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: a review and update. J Neurotrauma 1997;14:121-34
  • National Research Council, Canada. WO2005082860 (2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.